nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

19.03.2021 | Editorial

Clinical perspectives for the use of total body PET/CT

verfasst von: Ronan Abgral, David Bourhis, Pierre-Yves Salaun

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Excerpt

In the last decade, PET scanners have benefited from new technologies such as the TOF system, PSF correction, and SiPM detectors. More recently, the increase of detector number allowed an axial FOV as large as a human body length in a total-body PET (TB-PET) system. Two different scanners called Quadra© and uEXPLORER© have been respectively proposed by Siemens Healthineers and United Imaging Healthcare. These TB-PET have two major advantages over actual systems on the market: a gain in detection sensitivity and a possibility of whole-body dynamic multiple organs analysis [1, 2]. More than reducing drastically the acquisition duration and/or injected activities, these systems open up very interesting clinical perspectives to address specific issues encountered in routine clinical practice and thus improve patient care. …

Surti S, Pantel AR, Karp JS. Total Body PET: Why, how, what for? IEEE Trans Radiat Plasma Med Sci. 2020;4:283–92.PubMedPubMedCentralCrossRef

Vandenberghe S, Moskal P, Karp JS. State of the art in total body PET. Ejnmmi Phys. 2020;7:35.PubMedPubMedCentralCrossRef

Karakatsanis NA, Lodge MA, Tahari AK, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. Phys Med Biol. 2013;58:7391–418.PubMedPubMedCentralCrossRef

Karakatsanis NA, Lodge MA, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation. Phys Med Biol. 2013;58:7419–45.PubMedPubMedCentralCrossRef

Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.PubMedCrossRef

Karakatsanis NA, Zhou Y, Lodge MA, Casey ME, Wahl RL, Zaidi H, et al. Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. Phys Med Biol. 2015;60:8643–73.PubMedPubMedCentralCrossRef

Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, et al. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging. 2019;46:501–18.PubMedCrossRef

Karakatsanis NA, Casey ME, Lodge MA, Rahmim A, Zaidi H. Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation–maximization reconstruction. Phys Med Biol. 2016;61:5456–85.PubMedPubMedCentralCrossRef

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.PubMedCrossRef

10.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.PubMedCrossRef

11.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.PubMedCrossRef

12.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39.PubMedPubMedCentralCrossRef

13.

Salaün P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28–50.PubMedCrossRef

14.

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.PubMedCrossRef

15.

Viswanathan C, Faria S, Devine C, Patnana M, Sagebiel T, Iyer RB, et al. [18F]-2-Fluoro-2-Deoxy-D-glucose–PET assessment of cervical cancer. Pet Clin. 2018;13:165–77.PubMedPubMedCentralCrossRef

16.

Helsen N, den Wyngaert TV, Carp L, Stroobants S. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. Eur J Nucl Med Mol Imaging. 2018;45:1063–71.PubMedCrossRef

17.

Lell M, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol. 2000;33:239–47.PubMedCrossRef

18.

Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083.PubMedCrossRef

19.

Abgral R, Dweck MR, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Clinical utility of combined FDG-PET/MR to assess myocardial disease. JACC Cardiovasc Imaging. 2017;10:594–7.PubMedCrossRef

20.

Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2018;11:94–107.PubMedCrossRef

21.

Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383:705–13.PubMedCrossRef

22.

Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5.PubMedCrossRef

23.

Simoncic U, Perlman S, Liu G, Jeraj R. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Nucl Med Commun. 2015;36:1174–80.PubMedPubMedCentralCrossRef

24.

Roop MJ, Singh B, Singh H, Watts A, Kohli PS, Mittal BR, et al. Incremental value of cocktail 18F-FDG and 18F-NaF PET/CT over 18F-FDG PET/CT alone for characterization of skeletal metastases in breast cancer. Clin Nucl Med. 2017;42:335–40.PubMedCrossRef

25.

Karakatsanis NA, Abgral R, Trivieri MG, Dweck MR, Robson PM, Calcagno C, et al. Hybrid PET- and MR-driven attenuation correction for enhanced 18F-NaF and 18F-FDG quantification in cardiovascular PET/MR imaging. J Nucl Cardiol. 2020;27:1126–41.PubMedCrossRef

26.

Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.PubMedCrossRef

27.

Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor–directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.PubMedCrossRef

28.

Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2017;58:1452–8.PubMedPubMedCentralCrossRef

29.

Partelli S, Rinzivillo M, Maurizi A, Panzuto F, Salgarello M, Polenta V, et al. The role of combined 68Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology. 2015;100:293–9.CrossRef

30.

Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, et al. Performance of 18Fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96:665–71.PubMedCrossRef

31.

Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Bras ML, Régenet N, et al. Head-to-head comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in patients with midgut neuroendocrine tumors. Clin Nucl Med. 2020.

32.

Katzenellenbogen JA. PET imaging agents (FES, FFNP, and FDHT) for estrogen, androgen, and progesterone receptors to improve management of breast and prostate cancers by functional imaging. Cancers. 2020;12:2020.PubMedCentralCrossRef

33.

Evangelista L, Dieci MV, Guarneri V, Conte PF. 18F-Fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis. Curr Radiopharm. 2016;9:244–57.PubMedCrossRef

34.

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.PubMedCrossRef

35.

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.PubMedCrossRef

36.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204–10.PubMedCrossRef

37.

Thuillier P, Bourhis D, Karakatsanis N, Schick U, Metges JP, Salaun P-Y, et al. Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor. Medicine. 2020;99:e20021.PubMedPubMedCentralCrossRef

38.

Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019;9:1546–53.PubMedPubMedCentral

39.

Arias J-I, Aller M-A, Arias J. Surgical inflammation: a pathophysiological rainbow. J Transl Med. 2009;7:19.PubMedPubMedCentralCrossRef

40.

Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH. Radiation and inflammation. Semin Radiat Oncol. 2015;25:4–10.PubMedPubMedCentralCrossRef

41.

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;41:543–603.CrossRef

42.

Douketis JD, Ginsberg JS, Haley S, Julian J, Dwyer M, Levine M, et al. Accuracy and safety of 99mTc-labeled anti-D-dimer (DI-80B3) fab’ fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. Thromb Res. 2012;130:381–9.PubMedCrossRef

43.

Taillefer R, Edell S, Innes G, Lister-James J. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter trial investigators. J Nucl Med. 2000;41:1214–23.PubMed

44.

Brighton T, Janssen J, Butler SP. Aging of acute deep vein thrombosis measured by radiolabeled 99mTc-rt-PA. J Nucl Med. 2007;48:873–8.PubMedCrossRef

45.

Reuzé S, Schernberg A, Orlhac F, Sun R, Chargari C, Dercle L, et al. Radiomics in nuclear medicine applied to radiation therapy: methods, pitfalls, and challenges. Int J Radiat Oncol Biol Phys. 2018;102:1117–42.PubMedCrossRef

46.

Thuillier P, Roudaut N, Crouzeix G, Cavarec M, Robin P, Abgral R, et al. Malignancy rate of focal thyroid incidentaloma detected by FDG PET–CT: results of a prospective cohort study. Endocr Connect. 2017;6:413–21.PubMedPubMedCentralCrossRef

47.

Thuillier P, Bourhis D, Schick U, Alavi Z, Guezennec C, Robin P, et al. Diagnostic value of PET textural indices for malignancy of FDG-avid adrenal lesions. Q J Nucl Medicine Mol Imaging. 2019.

48.

Thuillier P, Bourhis D, Roudaut N, Crouzeix G, Alavi Z, Schick U, et al. Diagnostic value of FDG PET-CT quantitative parameters and Deauville-like 5 point-scale in predicting malignancy of focal thyroid incidentaloma. Front Med. 2019;6:24.CrossRef

49.

Dissaux G, Visvikis D, Da-ano R, Pradier O, Chajon E, Barillot I, et al. Pretreatment 18 F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non–small cell lung cancer: a multicentric study. J Nucl Med. 2019;61:814–20.PubMedCrossRef

50.

Grootjans W, Tixier F, van der Vos CS, Vriens D, Rest CCL, Bussink J, et al. The impact of optimal respiratory gating and image noise on evaluation of Intratumor heterogeneity on 18F-FDG PET imaging of lung cancer. J Nucl Med. 2016;57:1692–8.PubMedCrossRef

51.

Tromeur C, Sanchez O, Presles E, Pernod G, Bertoletti L, Jego P, et al. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. Eur Respir J. 2018;51:1701202.PubMedCrossRef

52.

Roux P-YL, Hicks RJ, Siva S, Hofman MS. PET/CT lung ventilation and perfusion scanning using Galligas and Gallium-68-MAA. Semin Nucl Med. 2018;49:71–81.PubMedCrossRef

53.

Roux P-YL, Robin P, Salaun P-Y. New developments and future challenges of nuclear medicine and molecular imaging for pulmonary embolism. Thromb Res. 2018;163:236–41.PubMedCrossRef

54.

Varnoux C, Huchon C, Bats AS, Bensaid C, Achouri A, Nos C, et al. Diagnostic accuracy of hand-assisted laparoscopy in predicting resectability of peritoneal carcinomatosis from gynecological malignancies. Eur J Surg Oncol. 2013;39:774–9.PubMedCrossRef

55.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2019;77:403–17.PubMedCrossRef

56.

Edeline J, Gilabert M, Garin E, Boucher E, Raoul J-L. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer. 2015;4:16–25.PubMedCrossRef

57.

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29.PubMedCrossRef

58.

Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46:1695–704.PubMedCrossRef

59.

de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503–13.PubMedCrossRef

60.

Robin P, Roux P-YL, Planquette B, Accassat S, Roy P-M, Couturaud F, et al. Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016;17:193–9.PubMedCrossRef

Titel: Clinical perspectives for the use of total body PET/CT
verfasst von: Ronan Abgral
David Bourhis
Pierre-Yves Salaun
Publikationsdatum: 19.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05293-4

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Clinical perspectives for the use of total body PET/CT

Excerpt

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI

18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

18F-FDG PET/CT and MRI findings of Shulman syndrome also known as eosinophilic fasciitis

Systematic imaging in medicine: a comprehensive review